GHK-Cu prescription: frequently asked questions.

Not for injectable GHK-Cu. As of April 2026, injectable GHK-Cu remains on the FDA Category 2 list, preventing compounding pharmacies from preparing it. Topical GHK-Cu does not require a prescription — it is available over the counter as Copper Tripeptide-1 in serums, creams, and scalp products. The pending Category 1 reclassification would restore injectable prescription access but has not been formalized.

Copper peptides and retinol can be used together, but should be applied at different times to avoid interaction. Retinol's acidic pH can destabilize the copper complex if applied simultaneously. The standard approach is to use copper peptide serum in the morning and retinol (retinol, retinal, or tretinoin) in the evening — or alternate days. This layering schedule allows both actives to work without chemical interference. Copper peptides and retinol are among the most commonly combined anti-aging actives when used with this separation strategy.

Copper peptides and vitamin C should NOT be applied simultaneously. Vitamin C (L-ascorbic acid) is a reducing agent at low pH that actively destabilizes the copper-peptide bond, potentially inactivating both the GHK-Cu and the vitamin C. If you want to use both, apply them at completely separate times — vitamin C in the morning, copper peptides in the evening, or on alternate days. Some derivative forms of vitamin C (like magnesium ascorbyl phosphate) are less reactive and may be more compatible, but the safest approach is temporal separation.

Category 1 status allows licensed compounding pharmacies to legally prepare GHK-Cu with a valid physician's prescription. This is NOT the same as full FDA drug approval, which requires Phase I–III clinical trials, formal safety and efficacy review, and standardized labeling. Category 1 compounds are legal to compound and prescribe but have not undergone the formal FDA approval process that prescription drugs like finasteride or tretinoin have completed.

Yes — the active molecule is identical: GHK-Cu (glycine-histidine-lysine bound to copper, INCI name Copper Tripeptide-1). The difference is delivery route and resulting tissue exposure. Topical serums are limited by skin barrier absorption and act locally on the epidermis and upper dermis. Injectable GHK-Cu bypasses the barrier entirely, delivering the full dose subcutaneously for systemic circulation and deep tissue access.

Based on comparable compounding pharmacy pricing, expect $150–$300 per month for self-administered subcutaneous GHK-Cu injection at standard dosing (1–2 mg daily). Scalp mesotherapy for hair restoration is significantly more expensive at $600–$1,400 per month during the treatment course due to in-clinic administration. Physician consultations ($100–$250 initial, $50–$100 follow-up) and lab work ($50–$150 per copper panel) are additional costs. Insurance will not cover compounded GHK-Cu.

Yes, once Category 1 reclassification is finalized. Telehealth peptide therapy providers were common prescribers of injectable peptides before the Category 2 restrictions. The process involves a video consultation, medical history review, lab order for baseline copper and metabolic panels, and electronic prescription to a licensed compounding pharmacy. No in-person visit is required in most states.

Yes. Topical GHK-Cu serums (0.1–2% concentration) are available now without a prescription and have 40+ years of clinical evidence for skin and hair applications. Look for products listing Copper Tripeptide-1 in the ingredients. Effective brands include those by NIOD, The Ordinary, and professional-grade compounding pharmacies. When injectable becomes available, the two routes complement each other — topical for daily skin-surface maintenance, injectable for systemic and deep-tissue effects.

The most common GHK-Cu injection side effects are mild injection site reactions: redness, tenderness, and swelling resolving within 24–48 hours. Less common: transient nausea, mild headache, skin flushing. Long-term use requires monitoring serum copper and ceruloplasmin levels every 4–6 weeks. GHK-Cu is contraindicated in Wilson's disease (copper metabolism disorder), pregnancy, active malignancy, and severe liver disease. The overall safety profile is favorable relative to most injectable therapies.